Trial Profile

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cytarabine (Primary) ; Cytarabine/daunorubicin (Primary) ; Daunorubicin (Primary) ; Tuspetinib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Acronyms MyeloMATCH; MyeloMATCH Screening Trial

03 Dec 2024 According to an Aptose Biosciences media release, the National Cancer Institute (NCI), part of the National Institutes of Health and Aptose Biosciences have entered into a Cooperative Research and Development Agreement (CRAD) under which the NCI and Aptose will collaborate on the clinical development of tuspetinib in myeloMATCH trial.
30 Oct 2024 The protocol has been amended to addition in Drug Arms.
06 Jun 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com